martes, 6 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 8, 2025

Is L3Harris the Best Defense Play Amid Increased Military Spending?

View original at finance.yahoo.com
Is L3Harris the Best Defense Play Amid Increased Military Spending? This article first appeared on GuruFocus. L3Harris Technologies (NYSE: LHX) may not carry the household name status of defence giants Lockheed or Raytheon, but I wouldn't mistake that for irrelevance…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Several analysts see upside to $280 range with some looking down to $212

    80% confidence

  • Forward EPS guidance appears conservative given strong order momentum and robust defense budget

    80% confidence

  • Recent analyst downward revisions tied to accounting adjustments, not underlying demand issues

    80% confidence

  • Wall Street has Strong Buy rating overall on L3Harris

    80% confidence

  • The Aerojet acquisition de-risks L3Harris business by adding long-cycle, platform-agnostic revenue stream

    80% confidence

  • L3Harris guidance represents about 7% growth in EPS

    80% confidence

  • L3Harris is initiating a Buy rating

    80% confidence

  • L3Harris may be underestimated by the market despite being well-positioned strategically

    80% confidence

  • L3Harris offers compelling mix of quality and growth, recommendation is Buy

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Is L3Harris the Best Defense Play Amid Increased Military Spending? — Source | Via News | es.VIA.NEWS